LA JOLLA, Calif.--(BUSINESS WIRE)--Regulus Therapeutics Inc. announced today that advancements from its leading microRNA platform and product pipeline were presented at the “6th Annual Meeting of the Oligonucleotide Therapeutics Society” held October 20 – 23, 2010 in Dana Point, California. Regulus and its collaborators presented new data on characteristics for anti-miR design, including oligonucleotide length and chemical modifications. Longer microRNA inhibitors (15 to 23 bases) were significantly more potent and efficacious in vitro and in vivo than shorter anti-miRs (8 bases) that only target the seed region of a microRNA.
